Senzime’s Year-End Report 2019
Financial information fourth quarter 2019
- Net sales amounts to KSEK 2,688 (2,671)
- Income after financial items amounts to KSEK -9,493 (-11,288)
- Earnings per share before dilution amounts to SEK -0.18 (-0.23)
Financial information January-December 2019
- Net sales amounts to KSEK 6,711 (3,214)
- Income after financial items amounts to KSEK -36,433 (-26,763)
- Earnings per share before dilution amounts to SEK -0.68 (-0.58)
- The Board of Directors proposes that no dividend to be paid for the financial year
Approved product registration of the TetraGraph in the US was the highlight of the quarter and a breakthrough for Senzime. The approval means that we can start selling the system in the world's largest market. Shortly thereafter, we were able to communicate that we have recruited a US General Manager who will establish Senzime in the US market, with sales both through distributors and directly to customers.
In January, we also finalized the registration of a wholly owned subsidiary, Senzime Inc., in Florida. The need for objective neuromuscular monitoring is very high in the United States and we are now looking forward to be a driving force in reducing anesthesia-related complications for millions of patients. We are ready with a very interesting product that meets great interest in the market, which is now rapidly adapting to the types of digital solutions we offer.
Major orders from Australia, Switzerland and South Korea, among others, have achieved our communicated target for 2019 of 300 delivered instruments and by the end of January 2020 we had delivered over 400 TetraGraph systems. Other orders during the year came from Japan, Sweden, Norway, Denmark, Finland, Spain and Italy. We have also recently signed distribution agreements with new partners in the UK and Poland.
I look forward to a very exciting 2020 with a continued focus on international expansion and to leverage the installed base of TetraGraph through recurring sales of TetraSens, our patented disposable electrodes.
Uppsala in February 2020, Pia Renaudin, CEO of Senzime AB (publ)
For further information, please contact:
Pia Renaudin, CEO
Tel: +46 70-813 34 17, e-post: firstname.lastname@example.org
Erik Bergman, CFO
Tel: +46 73-58 81 59, e-mail: email@example.com
TO THE EDITORS
Senzime develops and markets systems, driven by unique algorithms and sensors, to follow patients ' nervous systems and electrical impulses – before, during and after surgery. The company's solution is called TetraGraph, a medical technology system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow health care guidelines and drug recommendations, TetraGraph contributes to shorter hospitalizations and lower health care costs – in a world where everyone wakes up safely after surgery. The vision is a world without narcotics-related complications. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, firstname.lastname@example.org, is Certified Adviser for Senzime. www.senzime.com
This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on February 14, 2020, 08:45.